An interventional study of Multiplo HBc/HIV/HCV and Reveal HBsAg in HIV Infections, Hepatitis B Infections and Hepatitis C Infections, sponsored by MedMira Laboratories Inc.. Withdrawn at 4 sites in United States. Open to participants aged 13 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-21.
Sponsored by MedMira Laboratories Inc. · Not applicable, Interventional, and Diagnostic
The purpose of this study is to determine the efficacy of two rapid diagnostic tests in plasma, venipuncture whole blood, and fingerstick whole blood. The clinical performance of Multiplo HBc/HIV/HCV will be determined by comparing the results with patient infected status for HIV-1/2 (human immunodeficiency viruses 1 and 2), HBV (hepatitis B virus) and HCV (hepatitis C virus). The clinical performance of Reveal HBsAg will be determined by comparing the results with patient infected status for HBV.
Subject participation in the study will consist of a single one-hour visit, at which time blood samples will be drawn for testing with the investigational devices and with approved comparator assays. The test results, which are the outcome of the study, will be obtained only once, at the time of this visit.
The objective of this study is to determine the performance characteristics of two rapid diagnostic tests.
Approximately 3000-4500 subjects in total will be enrolled in the study into four different study populations. In Population 1, which is "at risk" group of about 2000-3000 subjects, roughly 2/3 will be individuals who are at risk of infection with HIV or hepatitis B or C, or who have signs or symptoms of hepatitis. Approximately 500 of these individuals are expected to be known HIV-positive individuals.
The remaining three study populations will be comprised of individuals with known infection with HIV (Population 1A, \~500 individuals), HBV (Population 1B, \~500 individuals), and HCV (Population 1C, \~500 individuals).
Both Multiplo HBc/HIV/HCV and Reveal HBsAg will be used to test finger stick whole blood, venous whole blood and plasma samples from each subject in Population 1. Plasma samples (repository or fresh) will be used to fulfill the requirements for Populations 1A, 1B, and 1C.
For all enrolled subjects, the plasma sample will be tested with the following FDA-approved assays: EIA for anti-HIV-1/2, anti-HCV, anti-HBc total, anti-HBc IgM, anti-HBs, and HBsAg. The efficacy of Multiplo will be determined by comparing the results with patient infected status for HIV-1/2, HBV and HCV. The efficacy of Reveal will be determined by comparing the results with patient infected status for HBV.
The primary analysis will involve comparison of Multiplo HBc/HIV/HCV and Reveal HBsAg results for each of the test markers (anti-HIV-1/2, anti-HCV, anti-HBc, and HBsAg), in each sample matrix (finger stick whole blood, venous whole blood and plasma) with the patient infected status as determined by separate algorithms for HIV, HBV, and HCV. The percent positive and percent negative agreement will be determined relative to patient infected status for each marker and sample type, with corresponding two-sided 95% confidence intervals.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
Browse Infections studies →MedMira Laboratories Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
All subjects:
Population 1 - Diagnostic Trial "At Risk" Group (n = 2000-3000)
Subjects must meet one or more of the following inclusion criteria to be enrolled in Population 1:
Population 1A - Additional known HIV-positive individuals (n = \~500)
Subjects must:
Population 1B - Additional known HBV-positive individuals (n = \~500)
Subjects must:
Population 1C - Additional known HCV-positive individuals (n = \~500)
Subjects must:
Exclusion Criteria:
Subjects tested with investigational devices and approved comparator assay algorithms for HIV and hepatitis B and C.
Device: Multiplo HBc/HIV/HCV and Reveal HBsAg
All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
Also known as: Multiplo Rapid HBc/HIV/HCV Antibody Test, Reveal Rapid Hepatitis B Surface Antigen Test
Clinical performance of Reveal HBsAg and Multiplo HBc/HIV/HCV
For each enrolled subject, Multiplo HBc/HIV/HCV and Reveal HBsAg devices will be used to test finger stick whole blood, venipuncture whole blood, and plasma samples. Plasma will also be tested using separate algorithms of FDA approved assays to determine patient infected status for HIV-1/2, hepatitis B, and hepatitis C. The performance of Reveal HBsAg will be determined relative to patient infected status for hepatitis B for each matrix assessed. The performance of Multiplo HBc/HIV/HCV will be determined relative to patient infected status for each of hepatitis B, HIV-1/2, and hepatitis C.
Time frame: At single study visit
This study is withdrawn, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MedMira Laboratories Inc.